Dyslipidemia, marked by irregular lipid levels including low-density lipoprotein (LDL) (Bosso et al., 2022; Higashi, 2023) and low-density lipoprotein receptor adapter protein 1 (LDLRAP1) (Ahangari et al., 2021) in the bloodstream, has been proposed as potentially linked to a heightened risk of AD (Oliveira et al., 2018; Wang et al., 2022). Here, LDLRAP1 is linked to Alzheimer disease.